Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TICEBA
Heidelberg, Baden-Württemberg, Germanyticeba.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
ABCB5-positive mesenchymal stem cells, developed and manufactured by TICEBA (now part of RHEACELL), have demonstrated anti-inflammatory and tissue-regenerative effects. Their cell therapy (AMESANAR®) is approved in Germany for chronic venous ulcers, and late-stage clinical trials (including pivotal Phase 3) are ongoing for epidermolysis bullosa (EBESANAR®); additional clinical studies are underway for other inflammation-driven and rare diseases.
- Therapeutic areas
- DermatologyEndocrinologyOphthalmologyCardiovascular
- Modalities
- Stem cell therapyMesenchymal stem cell therapyBiologic
- Industry
- Biotech
02
Partnerships
RHEACELL (primary development and clinical sponsor)
Beyond the preview
Go deeper on TICEBA.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TICEBA.